Spirits have held up better in past downturns, but they are now facing pressure from a smaller group of heavy users who are often among the first to seek medical treatment for obesity or metabolic disease
Future trials should take into account metabolic status, especially insulin resistance, and give priority to drugs that can reach the brain
FDA Warning Letters are publicly searchable in the FDA Warning Letters database
The limitation: Monoclonal antibodies are expensive to produce, and while bimagrumab only needs to be taken once every four weeks, it needs to be administered intravenously, which has to happen in a medical facility
Williams, C
[Pubmed] [StatPearls] Krajcovicov-Kudlckov, M., Blazcek, P., Kopcov, J., Bderov, A., & Babinsk, K